Physician profile
Keivan Abtahi
NPI 1295000560
$77,146.09
in general payments reported to CMS, 2019-2025
27 companies · $13K in 2025
The $13K reported for 2025 was more than what 89% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,396 · 2020: $1,755 · 2021: $1,143 · 2022: $4,946 · 2023: $33K · 2024: $21K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $13K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,215.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,560.00 |
| Travel and Lodging | $12,726.22 |
| Food and Beverage | $12,403.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $35,483.07 | 2019-2025 | Evos, Evos Mini, Trigen Intertan |
| Stryker Corporation | $34,288.04 | 2019-2025 | T2 Alpha, Axsos, Hoffmann |
| Osteocentric Technologies, INC. | $1,616.26 | 2024 | Osteocentric 4.0 X 130mm Locking Bone Screw Fastener St |
| Pylant Medical | $1,588.14 | 2022-2025 | |
| Medical Device Business Services, INC. | $1,350.00 | 2020 | |
| Depuy Synthes Sales INC. | $670.77 | 2019-2025 | Na, Tfn-Advance, Va-Lcp |
| Alafair Biosciences, INC. | $353.99 | 2024-2025 | Versawrap |
| Omnilife Science, INC | $303.00 | 2022-2024 | Corin Hips, Corin Knees |
| Polynovo North America LLC | $276.17 | 2024 | Novosorb Btm |
| Bone Support INC. | $256.21 | 2025 | Cerament G, Ceramentbone Void Filler |
| Acell, INC. | $182.29 | 2019 | |
| Shoulder Innovations, INC. | $152.27 | 2025 | Inset System |
| Bioventus LLC | $140.17 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Si-Bone, INC. | $80.53 | 2019-2021 | |
| Pacira Therapeutics, INC. | $70.91 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynasplint Systems INC. | $45.08 | 2019 | |
| Globus Medical, INC. | $43.69 | 2025 | Anthem |
| P Bar Medical LLC | $41.61 | 2025 | |
| Biocomposites INC | $38.66 | 2025 | Stimulan |
| Baxter Healthcare | $30.55 | 2025 | Tisseel |
| Integra Lifesciences Corporation | $24.66 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.33 | 2019-2020 | |
| Kci USA, INC. | $23.30 | 2019 | |
| Nuvasive Specialized Orthopedics, INC. | $17.77 | 2019 | |
| Medline Industries LP | $16.29 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.97 | 2020 | |
| Ferring Pharmaceuticals INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keivan Abtahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.